Form 4: Medpace Holdings CEO August J. Troendle Reports Stock Sales

August J. Troendle, CEO of Medpace Holdings, reported the sale of company stock in two transactions on May 24 and May 28, 2024.

Summary

• August J. Troendle, CEO of Medpace Holdings, filed a Form 4 detailing changes in beneficial ownership.
• On May 24, 2024, Troendle sold 3,987 shares of common stock at a weighted average price of $395.22.
• These shares were sold in multiple transactions ranging from $395.00 to $396.13.
• On May 28, 2024, Troendle sold 5,695 shares of common stock at a weighted average price of $395.49.
• These shares were sold in multiple transactions ranging from $395.00 to $396.33.
• Following these transactions, Troendle directly owns 654,656 shares of Medpace Holdings.
• Troendle also indirectly owns 4,733,019 shares through Medpace Investors, LLC.
• The sales were executed pursuant to a limit order placed by Troendle during an open window period.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock sales. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider. It's common for executives to periodically sell shares for personal financial management.

Stakeholder Impact

• The stock sales by the CEO could have a minor short-term impact on shareholder sentiment.

Key Dates